8-K: Amwell Announces Third Quarter 2024 Results, Revises Full-Year Guidance

Amwell reported its Q3 2024 financial results, showing a net loss of $44 million and revised its full-year revenue and EBITDA guidance.

Summary

• Amwell announced its financial results for the third quarter of 2024, reporting total revenue of $61 million.
• Subscription revenue reached $26.2 million, and Amwell Medical Group (AMG) visit revenue was $27.5 million.
• The company's gross margin was 37%.
• Amwell experienced a net loss of $44 million, an improvement from the $49.9 million loss in the previous quarter.
• Adjusted EBITDA was a loss of $31 million, also an improvement from the previous quarter's loss of $35 million.
• Total visits were 1.4 million, with approximately 70% of those visits occurring on the Converge platform.
• The company revised its full-year revenue guidance to a range of $247 to $252 million, down from the previous range of $259 to $269 million.
• AMG visit guidance was also revised to between 1.4 and 1.5 million, down from the previous range of 1.6 to 1.7 million.
• However, the company improved its full-year Adjusted EBITDA guidance to a range of ($137) million to ($142) million, from a previous range of ($150) million to ($145) million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are improvements in net loss and EBITDA compared to the previous quarter, the downward revision of revenue and visit guidance is concerning. The company is making progress on cost structure and platform adoption, but faces significant challenges in a competitive market.

Positives

• The company's net loss improved to $44 million from $49.9 million in the previous quarter.
• Adjusted EBITDA improved to a loss of $31 million from a loss of $35 million in the previous quarter.
• The company improved its full-year Adjusted EBITDA guidance.
• 70% of total visits were on the Converge platform, indicating successful platform adoption.

Negatives

• The company experienced a net loss of $44 million for the quarter.
• Full-year revenue guidance was revised down to $247-$252 million from $259-$269 million.
• Full-year AMG visit guidance was revised down to 1.4-1.5 million from 1.6-1.7 million.

Risks

• The company faces risks related to transitioning clients to the Converge platform without significant attrition.
• There are risks associated with renewing and upselling the client base.
• The company's relationship with the Defense Health Agency (DHA) beyond July 2025 is uncertain.
• The telehealth market is experiencing weak growth and increased volatility.
• The company must adapt to rapid technological changes and increased competition.
• Changes in healthcare laws and regulations pose a risk.
• Cybersecurity breaches could result in significant liability.
• The company's strategic transformation initiatives may not be successful.

Future Outlook

The company revised its full-year revenue guidance to $247-$252 million and AMG visits to 1.4-1.5 million, while improving its Adjusted EBITDA guidance to a loss of $137-$142 million.

Management Comments

• Ido Schoenberg, M.D., chairman and chief executive officer of Amwell, stated that Q3 was a busy quarter with steady execution on key strategies to become cash flow positive.
• Management is aligning the cost structure to fit the strategy, emphasizing efficiency and effectiveness.
• The company is building its growth organization to deliver high quality, higher margin revenue.
• Amwell is focused on executing and delivering for existing and new customers.
• The company is well underway in delivering the Defense Health Agency's Digital First Initiative with Leidos.

Industry Context

The announcement reflects the ongoing challenges and adjustments in the telehealth industry, with companies focusing on cost efficiency and platform adoption. Amwell's focus on its Converge platform and the DHA contract are key strategic initiatives in this competitive landscape.

Comparison to Industry Standards

• Amwell's revenue of $61 million is lower than some of its larger competitors in the telehealth space, such as Teladoc Health, which reported $660.6 million in revenue for Q3 2024.
• The adjusted EBITDA loss of $31 million is also a concern, as some competitors are closer to profitability or already profitable.
• Teladoc Health reported a net loss of $73.3 million in Q3 2024, which is higher than Amwell's loss, but Teladoc's revenue is significantly higher.
• The focus on platform adoption with 70% of visits on Converge is a positive sign, as platform integration is a key differentiator in the telehealth market.
• The revised guidance reflects the challenges in the telehealth market, with many companies facing slower growth than initially anticipated.

Related Party Transactions

• The document mentions related party transactions in accounts receivable and deferred revenue, but does not provide specific details.

Stakeholder Impact

• Shareholders may be concerned about the revised revenue and visit guidance, but encouraged by the improved EBITDA guidance.
• Employees may be impacted by the ongoing strategic transformation and cost-cutting measures.
• Customers will be impacted by the company's focus on platform adoption and service delivery.
• Suppliers and creditors will be impacted by the company's financial performance and cash flow.

Next Steps

• The company will host a conference call to discuss its financial results on October 30, 2024, at 5 p.m. ET.
• Amwell will continue to focus on executing its strategy, including the deployment of the Defense Health Agency's Digital First Initiative.

Key Dates

Keywords

telehealth, digital health, hybrid care, Amwell, financial results, revenue, EBITDA, Converge, healthcare, AMG, guidance